research News

HOUSTON, TX – CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced completion of planned enrollment in its global potentially pivotal study evaluating Berubicin, the Company’s novel anthracycline and the first anthracycline...
Paris, France – Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies, is delighted to announce that it is one of six organisations sharing $2.9 million in grants from the ALS Association that support the advancement of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS). The...
Laurel Hollow, NY – Cancer is insidious. Throughout tumor progression, the disease hijacks otherwise healthy biological processes—like the body’s immune response—to grow and spread. When tumors elevate levels of an immune system molecule called Interleukin-6 (IL-6), it can cause severe brain dysfunction. In about 50%-80% of cancer patients, this leads to...
Colorectal cancer rates are rising in adults under age 50 — people who are not typically screened for such cancers. The finding, gleaned from a cancer surveillance database and published in the June issue of Cancer Epidemiology Biomarkers & Prevention, reported a 17% increase in this age group over a...
New York, NY – Body dysmorphic disorder (BDD) is a debilitating mental illness characterized by an obsessive preoccupation with perceived flaws in one’s physical appearance. Patients with BDD often have distorted self-image, intrusive thoughts, and compulsive behaviors that significantly impair daily functioning and quality of life. Current therapies have limited...